Videos

Dr David Spigel reviews 3 of the most important, practice-changing topics at ASCO 2018: new therapies targeting RET in a number of tumor types, a prognostic biomarker assay to predict whether patients with breast cancer will need adjuvant hormonal therapy or chemotherapy, and the minimum level of PD-L1 positivity required to predict outcomes with immunotherapy in lung cancer.

Dr David Spigel considers how patient-reported outcomes, as well as palliative and supportive care, are revolutionizing cancer care so that consideration is being given to treating the patient, not just the cancer.

Dr David Spigel discusses the 2 major themes highlighted at ASCO 2018: the use of cancer biomarkers to achieve precision therapy, and fine tuning treatment of patients with immunotherapy with respect to who to treat, how to treat, and how to predict clinical outcomes.

Dr Thomas Bachelot is careful to set reasonable expectations for his patients with HR+/HER2- metastatic breast cancer regarding how long their treatment will last and how it will impact them.

Hope Rugo, MD, discusses common presenting symptoms of HR+/HER2- metastatic breast cancer, citing bone metastasis as the most prevalent.

The WCGIC chairperson, professor Eric Van Cutsem, MD, PhD, heads the Division of Digestive Oncology at University Hospitals Leuven and KU Leuven, Leuven, Belgium. He describes the difference between left- and right-sided colon cancers in terms of prognosis and response to therapy.

Dr. Valérie Vilgrain discusses SIRT Y-90 and the results of the SARAH trial.